This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
23 March 2017
In the March 2017 issue, the piece “A protein puzzle: Untangling the mysterious condition of amyloidosis” (Nat. Med. 23, 266–269, 2017) incorrectly stated that the FDA placed Ionis’ NEURO-TTR trial on hold. The FDA had placed a related trial called CARDIOTTR on hold after some patients in the NEURO-TTR trial developed complications. The error has been corrected in the HTML and PDF versions of this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chakradhar, S. A protein puzzle: Untangling the mysterious condition of amyloidosis. Nat Med 23, 266–269 (2017). https://doi.org/10.1038/nm0317-266
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0317-266
This article is cited by
-
Correction
Nature Medicine (2017)